|Day Low/High||13.98 / 14.31|
|52 Wk Low/High||9.98 / 19.14|
Company Received Additional Payment From SWK Funding LLC Based on Achievement of $25 Million Net Sales of NARCAN® Nasal Spray Milestone
Listing Strengthens IP Position and Enhances NARCAN Product Exclusivity
Overdoses kill 91 people a day.
Listing Bolsters IP Estate and Enhances NARCAN Product Exclusivity
Topline Data Expected in the First Half of 2018
Listings Significantly Strengthen IP Estate and Enhance NARCAN Product Exclusivity
Company Plans Additional Clinical Trials This Year; Topline Data Expected in 2018
Company to pursue up-listing to a major stock exchange in 2017
2mg Formulation Indicated for Patients At-Risk for Severe Opioid Withdrawal
SWK to Acquire Certain NARCAN® Royalties For Up to $17.5 Million
Thomas Brings Global Pharmaceutical and Financial Expertise to Opiant's Board
Listing Offers Product Exclusivity Until 2035
Approval Granted as Canada Confronts Opioid Crisis
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.